Project Grant R01DA062961
- This $142,100 Project Grant award from the National Institute of General Medical Sciences (CFDA 93.859 - Biomedical Research and Research Training) to East Tennessee State University is investigating the neuroinflammatory effects of polysubstance use disorders involving fentanyl and methamphetamine. The overarching goal is to understand the role of the pro-inflammatory cytokine tumor necrosis factor-alpha (TNFα) and the neuropeptide hypocretin/orexin (HCRT) in polysubstance-induced...
- The National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH), awarded a 5-year Project Grant of $184,706 to the University of North Carolina at Chapel Hill (UNC-CH) under the Drug Use and Addiction Research Programs (CFDA 93.279). The grant will fund research to investigate the impact of fentanyl consumption on noradrenergic plasticity in the basolateral amygdala, a key component of the stress response. Specifically, the project will develop a mouse model of...
- The National Institute on Drug Abuse (NIDA) awarded a $915,478 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to Brown University to evaluate the effectiveness and safety of different methadone treatment strategies, including dosing and expanded take-home flexibilities, for patients with opioid use disorder in the era of fentanyl. The project aims to address challenges in methadone initiation and maintenance for individuals with a history of fentanyl use, as...
- This $129,132 project grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) aims to characterize distinct subpopulations of dopamine neurons in the ventral tegmental area (VTA) and examine their unique responses to cocaine and fentanyl. Through single-nucleus RNA sequencing and fluorescent in situ hybridization techniques, the research will identify molecular markers that distinguish dopamine-only and dopamine-glutamate...
- This Project Grant award of $587,188.00 from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), supports a multi-omics research study on the impact of fentanyl use on cells susceptible to HIV infection. The research aims to evaluate the effects of fentanyl on the single-cell transcriptome and microRNA profiles in various peripheral blood mononuclear cell types, including CD4+ and CD8+ T lymphocytes, monocytes, B lymphocytes, dendritic...
- The National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH), awarded a $193,250 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to the Trustees of Tufts College, doing business as Tufts University School of Medicine in Boston, Massachusetts. The grant, awarded on September 15, 2025, aims to determine whether fentanyl overdose induces an anhedonic phenotype, which in turn increases the risk of relapse in individuals with opioid use...
- This Project Grant award, provided by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), will fund a clinical trial evaluating the impact of reduced methamphetamine use on various health outcomes. The $731,997 award will support a randomized, controlled 12-week trial with an additional 12-week follow-up period. The trial will assess improvements in cardiovascular health, immune function, sleep quality, and other psychosocial measures...
- This $147,486 federal Project Grant award from the National Institute on Drug Abuse (CFDA 93.279 - Drug Use and Addiction Research Programs) will support a mixed-methods study examining the predictors and outcomes of methadone and buprenorphine receipt during incarceration. The study will analyze a longitudinal database on health service use and outcomes among 4,558 incarcerated individuals who received these medications from 2016-2023 at a unified jail and prison system in the Northeast....
- This Project Grant award, totaling $400,294, was provided by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279). The funding supports research to investigate the neurobiological mechanisms by which adverse childhood experiences (ACEs) and chronic stress alter the rewarding effects of the synthetic opioid fentanyl. Specifically, the project aims to determine the therapeutic potential of the serotonin 2A receptor (5-HT2AR) in modulating...
- The National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH), awarded a $962,517 Cooperative Agreement under the Drug Use and Addiction Research Programs (CFDA 93.279) to Public Health Foundation Enterprises, Inc. (Heluna Health) to conduct a two-phase study on the use of the GLP-1 agonist semaglutide for treating methamphetamine use disorder (MEUD). The first phase will be an open-label, single-arm Phase IIA trial to evaluate the eligibility, adherence, and...
This federal Project Grant award of $457,701 from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), supports research to understand the pharmacodynamics of combined methamphetamine and fentanyl use. The primary objectives are to: 1) elucidate the mechanisms underlying polysubstance use disorders involving stimulants and opioids, and 2) investigate the role of the hypocretin/orexin neuropeptide system as a potential target for treating co-occurring stimulant and opioid use. The research will utilize a rat model of intravenous methamphetamine and fentanyl self-administration to examine the neurobiological and behavioral effects of polysubstance use. This 5-year project, awarded to East Tennessee State University, aims to provide critical insights into the underlying neurocircuitry driving the escalation of polysubstance use disorders, with the goal of informing the development of novel treatment interventions.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $457.7k | 8/1/25 |